Your search for gynecologic cancers matches 267 pages

Showing 201 - 250


gynecologic cancers

Bevacizumab in Persistent, Recurrent, or Metastatic Cervical Cancer

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On August 14, 2014, bevacizumab (Avastin) was approved for the...

gynecologic cancers

FDA Approves Bevacizumab for Aggressive and Late-Stage Cervical Cancer

The U.S. Food and Drug Administration (FDA) has approved the antiangiogenic agent bevacizumab (Avastin) for the treatment of persistent, recurrent, or metastatic cervical cancer. The new indication is approved for use in combination with paclitaxel and cisplatin or paclitaxel and topotecan. The FDA ...

gynecologic cancers

September Is Ovarian Cancer Awareness Month

In recognition of September as Ovarian Cancer Awareness month, David A. Fishman, MD, Director of the Mount Sinai Ovarian Cancer Risk Assessment Program and Professor and Fellowship Director in the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine at...

Breast Cancer
Gynecologic Cancers
Health-Care Policy

CDC’s Breast and Cervical Screening Program Benefits Millions of Underserved Women in the United States

More than 4.3 million women with limited access to health care received breast and cervical cancer screening and diagnostic services in the first 20 years of the Centers for Disease Control and Prevention (CDC) National Breast and Cervical Cancer Early Detection Program. From 1991 to 2011, 56,662...

Gynecologic Cancers
Global Cancer Care

Rwanda Offers Women Free Cervical Cancer Screening, HPV Vaccination

Cervical cancer is one of the major killers among women in Rwanda, and with the support of Rwanda’s First Lady, Jeannette Kagame, the country is rolling out a free human papillomavirus (HPV) vaccination and cervical cancer screening program in collaboration with Marck, Qiagen (a Dutch...

gynecologic cancers

Adding Antiangiopoietin Agent Trebananib to Paclitaxel Improves Progression-Free Survival in Recurrent Epithelial Ovarian Cancer

Trebananib inhibits angiogenesis by blocking the binding of angiopoietins 1 and 2 to the Tie2 receptor expressed on endothelial cells, a mechanism that differs from vascular endothelial growth factor (VEGF) inhibitors and that involves a different signaling pathway. In the phase III TRINOVA-1 trial ...

gynecologic cancers

Angiogenesis in Ovarian Cancer: Are We Missing the Clinical Target?

Production of vascular endothelial growth factor (VEGF) is increased during normal ovulation, and can account for much of the reversible toxicity associated with ovarian hyperstimulation.1,2 We also have compelling data from multiple clinical trials to validate the importance of tumor-associated...

gynecologic cancers

Early Study Finds Olaparib Tablet Safe in Pretreated Ovarian Cancer Patients; More Effective in Those With BRCA Mutations

An oral tablet form of a poly-ADP ribose polymerase (PARP) inhibitor, olaparib, given in combination with chemotherapy, was safe in heavily pretreated patients with ovarian cancer, and patients with BRCA mutations may have a better response compared with those without a BRCA mutation, according to...

gynecologic cancers

Novel Immunotherapy for Ovarian Cancer Receives Fast Track Designation

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin for the treatment of women with ovarian cancer whose disease has progressed on or recurred after...

gynecologic cancers

In Managing Ovarian Cancer, Precision Medicine Is a Work in Progress

Precision medicine in the management of ovarian cancer “is a work in progress, to be sure,” Steven B. Newman, MD, noted in wrapping up the session on gynecologic cancer at the recent Best of ASCO meeting in Chicago. “A list of different histologic types of ovarian cancer and potential targets are...

breast cancer
colorectal cancer
gynecologic cancers
prostate cancer

Overscreening for Prostate, Breast, Colorectal, and Cervical Cancer Can Raise Costs and Harm Patients

Analyses of data from 27,404 people aged 65 and older participating in the National Health Interview Survey (NHIS) from 2000 through 2010 suggest that overscreening for prostate, breast, cervical, and colorectal cancer screening “is common in both men and women, which not only increases health care ...

gynecologic cancers

Nine-Valent HPV Vaccine May Prevent Nearly 90% of Cervical Cancers

Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to research published in Cancer Epidemiology, Biomarkers...

gynecologic cancers

Genetic ‘Hotspot’ Linked to Endometrial Cancer Aggressiveness

Parents of twins often tell them apart through subtle differences such as facial expression, moles, voice tone, and gait. Similarly, physicians treating women with endometrial cancer must be able to distinguish between different versions of this disease form that, on the surface, appear the same....

gynecologic cancers

Woman With Ovarian Tumor, Daguerreotype, Wellington, Ohio, June 1851

In June 1851, Philip J. Bruckner, MD, hired a daguerreotypist to photograph this 275-pound, 33-year-old woman, who had borne five children while developing this massive tumor. Dr. Bruckner learned of this patient when Charles Breech, MD, of Wellington, Ohio, presented her case at a medical meeting. ...

gynecologic cancers

Attaining the Goal of Preventing Ovarian Cancer

Fifteen years ago, David Fishman, MD, launched the National Ovarian Cancer Early Detection Program as part of the National Cancer Institute’s Early Detection Research Network. The goal of the research effort was to develop methods to accurately detect ovarian cancer while it was still confined to...

gynecologic cancers

Call for Ideas for Ovarian Cancer Translational Research ‘Dream Team’ Grant

The American Association for Cancer Research (AACR) is accepting submissions of ideas for the Stand Up To Cancer–Ovarian Cancer Research Fund–Ovarian Cancer National Alliance–National Ovarian Cancer Coalition (SU2C-OCRF-­OCNA-NOCC) Translational Research Dream Team Grant that will offer up to $6...

cns cancers
gynecologic cancers
lung cancer

Aldoxorubicin Receives FDA Orphan Drug Designations for Glioblastoma, Small Cell Lung Cancer, and Ovarian Cancer

The U.S. Food and Drug Administration has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and specifically to...

gynecologic cancers

Cervical Cancer Risks After Negative HPV Test Lower at 3 Years Than After Negative Pap Result

Three-year risks for cervical cancer and cervical intraepithelial neoplasia grade 3 or worse (CIN3+) were lower following a negative test for human papillomavirus (HPV) than following a negative Pap test, according to a large study comparing three cervical cancer screening strategies, HPV or Pap...

gynecologic cancers

NIH 2014 New Innovator Award Recipient Pamela Kreeger, PhD, to Study Metastasis in Ovarian Cancer

Pamela Kreeger, PhD, Assistant Professor of Biomedical Engineering at the University of Wisconsin-Madison, is among a group of researchers to receive a 2014 New Innovator Award from the National Institutes of Health. Dr. Kreeger will receive funding of nearly $2.3 million. She has chosen to study...

gynecologic cancers

Encouraging Early Signals for Cediranib in Recurrent Cervical Cancer

Cediranib (a potent tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3) produced a modest improvement in progression-free survival and a robust improvement in response rates compared with placebo when added to chemotherapy in patients with recurrent...

gynecologic cancers

Pazopanib Maintenance Improves Progression-Free Survival in Ovarian Cancer

In a phase III trial reported in the Journal of Clinical Oncology, ­Andreas du Bois, MD, PhD, Professor of Gynecologic Oncology at Kliniken Essen-Mitte in Essen, Germany, and colleagues found that maintenance therapy with the vascular endothelial growth factor receptor (VEGFR) and platelet-derived...

gynecologic cancers

Maintenance Therapy in Ovarian Cancer: What’s at Stake?

Maintenance therapy in ovarian cancer refers to a cohort of women achieving response to initial adjuvant chemotherapy who then go on to additional therapy in the hopes of extending time to recurrence or inducing a lasting remission. The concept is not new and retains its scientific and clinical...

gynecologic cancers

Scientists Develop New Approach to Treating HPV-Related Cervical Cancer

Cidofovir, an antiviral drug that is well established as a treatment for infection of the retina in people with AIDS, has been shown to be effective in combination with chemoradiation in a phase I study of women with human papillomavirus (HPV)-related cervical cancer. The study results were...

gynecologic cancers

Cancer-Killing Virus Plus Chemotherapy Studied in Recurrent Ovarian Cancer

In 6 out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and 5-year survival is only 27%. A new study suggests that a cancer-killing virus combined with a chemotherapy drug might safely and effectively treat advanced or recurrent forms of the disease. Researchers at The Ohio...

gynecologic cancers

With New Innovator Award, Biomedical Engineer to Study How Ovarian Cancer Spreads

With approximately 22,000 diagnoses annually in the United States, ovarian cancer isn’t among the most commonly occurring cancers. Yet, the mortality rate for women who have ovarian cancer hovers above 60%. For Pamela Kreeger, PhD, a University of Wisconsin–Madison Assistant Professor of Biomedical ...

gynecologic cancers

FDA Approves Bevacizumab Plus Chemotherapy for Platinum-Resistant, Recurrent Ovarian Cancer

The U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The approval...

gynecologic cancers

Dual HER2 Targeting Inhibits HER2-Amplified Uterine Serous Carcinoma

In a study reported in Clinical Cancer Research, Groeneweg and colleagues found that dual HER2 targeting showed greater activity than a single agent in HER2-amplified uterine serious carcinoma. In the study, ARK1, ARK2, and SPEC2 cell lines were treated with trastuzumab (Herceptin) or lapatinib...

gynecologic cancers

Electro-Gynecology, Philadelphia, 1883

Through the Lens of Oncology History A Century of Progress The text and photographs on these pages represent the establishment of oncology as a viable medical specialty during the mid-1800s. The images and captions are excerpted from a four-volume series of books titled Oncology Tumors &...

gynecologic cancers

Ovarian Cancer Has Taught Me to Be Fearless

In 2013, I was at the top of my professional game. I was a lead performer in the hit Broadway show Motown: The Musical, playing singing legend Diana Ross, which earned me a Tony Award nomination. Performing eight shows a week is exhausting, but I had no problem meeting the physical demands of the...

gynecologic cancers

Olaparib for BRCA-Mutated Previously Treated Advanced Ovarian Cancer

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 19, 2014, olaparib (Lynparza) was granted accelerated...

gynecologic cancers

Gardasil 9 Adds Protection Against Cancer Caused by Additional Human Papillomavirus Types

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On December 10, 2014, Gardasil 9 (human papillomavirus 9-valent ...

breast cancer
gynecologic cancers

Study Finds Whole-Genome Sequencing Is Successful in Identifying Patients’ Risk for Inherited Cancers

A study by researchers at The University of Texas Southwestern Medical Center in Dallas and The Ohio State University in Columbus of whole-genome sequencing on patients found to have BRCA1 or BRCA2 mutations as well as on those who were not carriers of a BRCA1/2 mutation has found cancer risk of...

gynecologic cancers

FDA Approves Companion Diagnostic for the Detection of BRCA1/2 Mutations in Ovarian Cancer

The recent U.S. Food and Drug Administration (FDA) of olaparib (Lynparza) occurred concurrently with that of a companion diagnostic, BRACAnalysis CDx. This genetic test is designed to detect the presence of mutations in the BRCA genes in blood samples from patients with ovarian cancer. The BRCA...

gynecologic cancers

FDA Approves Olaparib to Treat BRCA-Mutated Advanced Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to olaparib (Lynparza) for women with advanced ovarian cancer with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, as detected by an FDA-approved test, who have been treated with three...

Gynecologic Cancers

Zoledronic Acid Inhibits Angiogenesis in Ovarian Cancer Patients

The bisphosphonate zoledronic acid has been reported to produce antitumor effects, although the mechanisms of such effects remain unclear. In a study reported in Clinical Cancer Research, Gonzalez-Villasana and colleagues found evidence that zoledronic acid inhibited ovarian cancer angiogenesis by...

Gynecologic Cancers

Moffitt Cancer Center Reports on Faculty Participants in International Discovery of Genetic Risk Factors for Ovarian Cancer

Researchers from Moffitt Cancer Center in Tampa, Florida have participated in a global effort that has identified six new regions of the genome that increase risk of epithelial ovarian cancer, according to a news release from Moffitt. The collaborative study was published recently in Nature...

gynecologic cancers
survivorship

High-Quality Diet Before Ovarian Cancer Diagnosis May Lengthen Survival

An overall high-quality diet at least 12 months before a diagnosis of ovarian cancer “was associated with a statistically significant 27% lower risk of death after ovarian cancer,” an analysis of dietary data from the Women’s Health Initiative showed. The protective effect was strongest among women ...

survivorship
gynecologic cancers

Cancer Was My Wake-Up Call to a Healthier Life

I come from strong physical stock and inherited a sort of “tough it out mentality” when it comes to coping with the usual aches and pains that creep up as you age. So by the time I realized that my legs had become so swollen and my breathing so labored it was difficult for me to walk, I could...

gynecologic cancers
pancreatic cancer

Human Reovirus Formulation Gets Orphan Drug Designation in Ovarian and Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for Oncolytics Biotech’s proprietary formulation of the human reovirus (Reolysin) for the treatment of ovarian and pancreatic cancer. The reovirus’s primary mode of activity is to infect and selectively target tumors...

gynecologic cancers

FDA Grants Breakthrough Therapy Designation to Rucaparib in Advanced Ovarian Cancer With BRCA Mutations

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Clovis Oncology’s investigational agent rucaparib as monotherapy treatment of advanced ovarian cancer in patients who have received at least two lines of prior platinum-containing therapy, with ­BRCA-mutated ...

gynecologic cancers

Complete Regression of Metastatic Cervical Cancer Is Observed After Treatment With HPV-Targeted Tumor-Infiltrating T Cells

As reported in the Journal of Clinical Oncology,1 researchers at the National Cancer Institute observed complete regression of metastatic cervical tumors in two patients following a single infusion of human papillomavirus (HPV)-targeted tumor-infiltrating T cells. In the protocol, nine patients...

gynecologic cancers

Robert Coleman, MD, Begins SGO and Foundation Presidency

Robert L. Coleman, MD, Professor, Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, started his 1-year term as the 47th President of the Society of Gynecologic Oncology (SGO) and 5th President of the Foundation for Gynecologic...

gynecologic cancers
issues in oncology

Bombarded With Changes in Health Care and Beyond, Gynecologic Oncologists Prepare for the Challenges Ahead

Physicians are being “bombarded” with changes in health care and beyond, Richard R. Barakat, MD, FACS, noted in his Presidential Address at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. These changes are being precipitated by steeply rising health-care costs amid...

gynecologic cancers

Groups Join Together to Form Ovarian Cancer Research Team

Stand Up To Cancer , Ovarian Cancer Research Fund, Ovarian Cancer National Alliance, and National Ovarian Cancer Coalition, along with the American Association for Cancer Research (AACR), announced the formation of a “Dream Team” devoted to ovarian cancer research at the AACR Annual Meeting 2015....

gynecologic cancers

Combining Antiangiogenic and Vascular-Disrupting Agents Improves Progression-Free Survival in Persistent Ovarian Cancer

“Bevacizumab [Avastin] prevents new blood vessels from growing, but what about the blood vessels that are already in the tumor?” Presenting that challenge to participants at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Chicago, Bradley J. Monk, MD, of the University of...

Gynecologic Cancers

Immunosignature Technology May Detect Ovarian Cancer With a Drop of Blood

“Immunosignatures” may be well suited to enable the detection of ovarian cancer, researchers reported at the National Comprehensive Cancer Network (NCCN) 20th Annual Conference.1 “We developed a new concept for disease detection based on immunosignatures. From a drop of blood, HealthTell’s...

breast cancer
gynecologic cancers
kidney cancer
skin cancer
cost of care

NCCN Posters of Interest Included Studies in Kidney, Breast, and Endometrial Cancers, Melanoma, and Cost Issues

The quality and quantity of original research presented at the National Comprehensive Cancer Network (NCCN) Annual Conference continue to grow since poster sessions debuted a few years ago. The ASCO Post offers summaries for just a few that caught our eye, out of more than 65 presented this year....

Gynecologic Cancers

PARP Inhibitors: The First Potential Treatment of Hereditary Ovarian Cancers

Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting new classes of agents in development for the treatment of ovarian cancer. Olaparib (Lynparza), the lead oral PARP inhibitor, received accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of...

Gynecologic Cancers

American College of Physicians Releases Best Practice Advice for Cervical Cancer Screening in Average-Risk Women

In April 2015, the American College of Physicians (ACP) released its clinical advice guideline, Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.1 The guideline aims to reduce the overuse of cervical...

Gynecologic Cancers

PARP Inhibitors Have ‘Clear Benefit’ for Patients With Ovarian Cancer and BRCA Mutations, but When and at What Cost?

PARP inhibitors offer a promising alternative for targeted therapy in ovarian cancer” and have “clear benefit in BRCA-mutation carriers,” but questions remain about when is the best time to use them and the cost-effectiveness of maintenance therapy, Elizabeth M. Swisher, MD, of the University of...

Advertisement

Advertisement



Advertisement